 |
|
|
| |
High SVR Rates With Eight and Twelve Weeks of Pangenotypic Glecaprevir/Pibrentasvir:
Integrated Efficacy Analysis of Genotype 1-6 Patients Without Cirrhosis
|
| |
| |
Reported by Jules Levin
EASL 2017 April19-23 Amsterdam Netherlands
Massimo Puoti 1, Graham R Foster2, Stanley Wang3, David Muti mer4, Edward Gane5, Christophe Moreno6, Ting Tsung Chang7, Sam Lee8, Rui Marinho9, Jean-Francois DuFour10, Stanislas Pol11, Christophe Hezode12, Stuart C Gordon13, Simone I Strasser14, Paul J Thuluvath15, Ran Liu3, Tami Pilot-Matias3, Federico Mensa3
1AO Ospedale Niguarda Ca Granda, Milan, Italy; 2Queen Mary University of London, Barts Health, London, United Kingdom; 3AbbVie Inc., North Chicago, Illinois, United States; 4Queen Elizabeth Hospital and NIHR Liver Biomedical Research Unit, Birmingham, United Kingdom; 5University of Auckland, Auckland, New Zealand; 6CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium; 7National Cheng Kung University Hospital, Tainan City, Taiwan; 8University of Calgary, Calgary, Alberta, Canada; 9Hospital S. Maria, Medical School of Lisbon, Portugal; 10Hepatology, University Clinic for Visceral Surgery and Medicine, Bern University Hospital, Switzerland; 11Groupe Hospitalier Cochin-Saint Vincent De Paul, Paris, France; 12Hôpital Henri Mondor, AP-HP, Université Paris-Est, Créteil, France; 13Henry Ford Health System, Detroit, Michigan, United States; 14Royal Prince Alfred Hospital, Sydney, Australia; 15Mercy Medical Center & University of Maryland School of Medicine, Baltimore, Maryland, United States
|
| |
|
|
|
|
|
